➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

Litigation Details for Nabi Biopharmaceuticals v. Roxane Laboratories, Inc (S.D. Ohio 2005)

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Nabi Biopharmaceuticals v. Roxane Laboratories, Inc (S.D. Ohio 2005)

Docket   Start Trial Date Filed 2005-09-26
Court District Court, S.D. Ohio Date Terminated 2008-02-29
Cause 35:271 Patent Infringement Assigned To Edmund A. Sargus Jr.
Jury Demand None Referred To Magistrate Judge Terence P Kem
Patents 4,870,105; 6,576,665; 6,875,445
Attorneys Amanda J. Hollis; Bryan R Faller; George C Best; Heidi R. Strain; James Allison Wilson , Jr; James Dodds Curphey; Jeremy J. Edwards; Kenneth G Schuler; Liane Marie Peterson; Matthew Marlowe; Mitchell Matorin; Robert Ward Trafford; Sarah Cooleybeck; Stephen B Deutsch; Steven A Maddox; Steven C. Cherny; Vickie L Henry
Firms Foley & Lardner; Foley & Lardner, LLP; Foley Hoag LLP; Kirkland & Ellis LLP; Latham & Watkins LLP; Latham and Watkins; Mitchell Matorin; Porter Wright Morris & Arthur - 2; Stephen B Deutsch; Vorys Sater Seymour and Pease LLP; Washington Harbour
Link to Docket External link to docket
Small Molecule Drugs cited in Nabi Biopharmaceuticals v. Roxane Laboratories, Inc
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Nabi Biopharmaceuticals v. Roxane Laboratories, Inc (S.D. Ohio 2005)

Date Filed Document No. Description Snippet Link To Document
2005-09-26 1 6,576,665 (the “’665 patent”), assigned to plaintiff Nabi, which has the right and standing to enforce…respect to a patent constitutes an act of patent infringement under Section 271(e) of the Patent Act. 35 U.S.C…NABI’S PATENT 7. Roxane’s submission of its ANDA constitutes infringement of United States Patent No. 6,576,665…enforce the ’665 patent. A copy of the ’665 patent is attached as Exhibit A. 8. In addition, Nabi has standing…or more claims of the ’665 patent under the Hatch- Waxman Act and the Patent Act. 35 U.S.C. § 271(e)(2) External link to document
2007-02-14 111 acetate product upon expiration of U.S. Patent No. 4,870,105. Roxane responded to the first two interrogatories… able to launch its product as soon as patent number 4,870,105 expires. Nabi asserts that…infringes either of two patents held by the plaintiffs (the ‘665 patent and the ‘445 patent) and whether the …market upon the expiration of a different patent (the ‘105 patent) in April, 2007, Nabi has attempted to …product did not infringe any of Nabi’s patents other than the ‘105 patent, but nonetheless filed this suit External link to document
2007-03-21 142 its alleged rights under U.S. Patent No. 1 4,870,105 (the 105 patent). Upon information and belief, …Nabi holds three patents for PhosLo: Patent No. 4,879,105 (the “105 patent”); Patent No. 6,576,665 (the…the “665 patent”); and Patent No. 6,875,445 (the “445 patent”). The 105 patent is scheduled to expire …will also infringe U.S. Patent No. 6,875,445 (the 445 patent). The 445 patent is not listed as part of…injunctive relief for alleged patent infringement under Section 271 (e) of the Patent Act, 35 U.S.C. § 27l(e) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.